Grand Hyatt, São Paulo, Brazil

September 3-4, 2019

0
days
0
hours
0
minutes
0
seconds

Presenting Companies

ISLA Pharmaceuticals, a Puerto Rico based company, is developing products for the prevention and treatment of
mosquito borne illnesses. With a lead molecule that has been examined in approximately 10,000 subjects for other indications but never approved, ISLA will initiate a Phase 2 clinical trial to explore the activity of this molecule in dengue patients in late 2019 or early 2020. This molecule shows pre-clinical activity in a number of closely related viruses and as such may have broad applicability against a variety of different viruses that afflict millions of people each year.